STOCK TITAN

[Form 4] Niagen Bioscience, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Niagen Bioscience, Inc. (NAGE) — Form 4 insider filing: On 06/24/2025, director Hamed Shahbazi received an award of 20,000 non-qualified stock options with an exercise price of $14.13 per share. The grant vests 100 % on 06/24/2026 and expires on 06/23/2035. After the transaction, Shahbazi beneficially owns 20,000 derivative securities; no change in common-stock holdings was reported. The transaction was filed individually and reported as a new award (transaction code “A”). This filing reflects standard director compensation and introduces limited potential dilution (≈0.0x % of shares outstanding, assuming a typical small-cap base) once exercised.

Niagen Bioscience, Inc. (NAGE) — Comunicazione interna Form 4: Il 24/06/2025, il direttore Hamed Shahbazi ha ricevuto un premio di 20.000 opzioni azionarie non qualificate con un prezzo di esercizio di $14,13 per azione. L'assegnazione matura interamente il 24/06/2026 e scade il 23/06/2035. Dopo la transazione, Shahbazi detiene beneficiariamente 20.000 titoli derivati; non è stato segnalato alcun cambiamento nella detenzione delle azioni ordinarie. La transazione è stata presentata individualmente ed è stata riportata come nuovo premio (codice transazione “A”). Questa comunicazione riflette la normale compensazione del direttore e introduce una diluizione potenziale limitata (≈0,0% delle azioni in circolazione, considerando una base tipica di small cap) una volta esercitate.

Niagen Bioscience, Inc. (NAGE) — Presentación interna Formulario 4: El 24/06/2025, el director Hamed Shahbazi recibió una concesión de 20,000 opciones sobre acciones no calificadas con un precio de ejercicio de $14.13 por acción. La concesión se consolida 100 % el 24/06/2026 y vence el 23/06/2035. Tras la transacción, Shahbazi posee beneficiosamente 20,000 valores derivados; no se reportaron cambios en la tenencia de acciones ordinarias. La transacción se presentó de forma individual y se reportó como una nueva concesión (código de transacción “A”). Esta presentación refleja la compensación estándar para directores e introduce una dilución potencial limitada (≈0,0 % de las acciones en circulación, asumiendo una base típica de pequeña capitalización) una vez ejercidas.

Niagen Bioscience, Inc. (NAGE) — 내부자 신고서 Form 4: 2025년 6월 24일, 이사 Hamed Shahbazi는 주당 $14.13의 행사가격으로 20,000개의 비자격 주식매수선택권을 수여받았습니다. 이 부여는 2026년 6월 24일에 100% 취득되며 2035년 6월 23일에 만료됩니다. 거래 후 Shahbazi는 20,000개의 파생 증권을 실질적으로 보유하고 있으며, 보통주 보유에는 변화가 보고되지 않았습니다. 이 거래는 개별적으로 신고되었으며 신규 수여(거래 코드 “A”)로 보고되었습니다. 이 신고는 표준 이사 보상을 반영하며 행사 시 제한적인 희석 가능성(전체 발행 주식의 약 0.0%로 추정, 일반적인 소형주 기준)을 나타냅니다.

Niagen Bioscience, Inc. (NAGE) — Déclaration d’initié Formulaire 4 : Le 24/06/2025, le directeur Hamed Shahbazi a reçu une attribution de 20 000 options d’achat d’actions non qualifiées au prix d’exercice de 14,13 $ par action. L’attribution vest à 100 % le 24/06/2026 et expire le 23/06/2035. Après la transaction, Shahbazi détient bénéficiairement 20 000 titres dérivés ; aucun changement dans la détention d’actions ordinaires n’a été signalé. La transaction a été déposée individuellement et rapportée comme une nouvelle attribution (code transaction « A »). Ce dépôt reflète la rémunération standard des administrateurs et introduit une dilution potentielle limitée (≈0,0 % des actions en circulation, en supposant une base typique de small cap) une fois exercée.

Niagen Bioscience, Inc. (NAGE) — Insider-Meldung Form 4: Am 24.06.2025 erhielt der Direktor Hamed Shahbazi eine Zuteilung von 20.000 nicht qualifizierten Aktienoptionen mit einem Ausübungspreis von 14,13 $ pro Aktie. Die Zuteilung wird zu 100 % am 24.06.2026 fällig und läuft am 23.06.2035 ab. Nach der Transaktion hält Shahbazi wirtschaftlich 20.000 derivative Wertpapiere; keine Änderung bei den Stammaktien wurde gemeldet. Die Transaktion wurde einzeln gemeldet und als neue Zuteilung (Transaktionscode „A“) ausgewiesen. Diese Meldung spiegelt die übliche Vergütung von Direktoren wider und führt nach Ausübung zu einer begrenzten potenziellen Verwässerung (≈0,0 % der ausstehenden Aktien, basierend auf einer typischen Small-Cap-Basis).

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine 20k-option grant to director; minimal immediate impact.

The Form 4 discloses a standard equity-compensation grant—20,000 options at $14.13—to director Hamed Shahbazi. Vesting after one year encourages continued board service and further aligns the director’s incentives with shareholder value creation. Because the award represents a small fraction of expected shares outstanding and is non-cash, it does not affect current liquidity or capital structure. Dilution will only occur if the share price exceeds $14.13 and the options are exercised, likely years out. No open-market buying or selling took place, so the filing offers little signal on management’s near-term view of valuation.

Niagen Bioscience, Inc. (NAGE) — Comunicazione interna Form 4: Il 24/06/2025, il direttore Hamed Shahbazi ha ricevuto un premio di 20.000 opzioni azionarie non qualificate con un prezzo di esercizio di $14,13 per azione. L'assegnazione matura interamente il 24/06/2026 e scade il 23/06/2035. Dopo la transazione, Shahbazi detiene beneficiariamente 20.000 titoli derivati; non è stato segnalato alcun cambiamento nella detenzione delle azioni ordinarie. La transazione è stata presentata individualmente ed è stata riportata come nuovo premio (codice transazione “A”). Questa comunicazione riflette la normale compensazione del direttore e introduce una diluizione potenziale limitata (≈0,0% delle azioni in circolazione, considerando una base tipica di small cap) una volta esercitate.

Niagen Bioscience, Inc. (NAGE) — Presentación interna Formulario 4: El 24/06/2025, el director Hamed Shahbazi recibió una concesión de 20,000 opciones sobre acciones no calificadas con un precio de ejercicio de $14.13 por acción. La concesión se consolida 100 % el 24/06/2026 y vence el 23/06/2035. Tras la transacción, Shahbazi posee beneficiosamente 20,000 valores derivados; no se reportaron cambios en la tenencia de acciones ordinarias. La transacción se presentó de forma individual y se reportó como una nueva concesión (código de transacción “A”). Esta presentación refleja la compensación estándar para directores e introduce una dilución potencial limitada (≈0,0 % de las acciones en circulación, asumiendo una base típica de pequeña capitalización) una vez ejercidas.

Niagen Bioscience, Inc. (NAGE) — 내부자 신고서 Form 4: 2025년 6월 24일, 이사 Hamed Shahbazi는 주당 $14.13의 행사가격으로 20,000개의 비자격 주식매수선택권을 수여받았습니다. 이 부여는 2026년 6월 24일에 100% 취득되며 2035년 6월 23일에 만료됩니다. 거래 후 Shahbazi는 20,000개의 파생 증권을 실질적으로 보유하고 있으며, 보통주 보유에는 변화가 보고되지 않았습니다. 이 거래는 개별적으로 신고되었으며 신규 수여(거래 코드 “A”)로 보고되었습니다. 이 신고는 표준 이사 보상을 반영하며 행사 시 제한적인 희석 가능성(전체 발행 주식의 약 0.0%로 추정, 일반적인 소형주 기준)을 나타냅니다.

Niagen Bioscience, Inc. (NAGE) — Déclaration d’initié Formulaire 4 : Le 24/06/2025, le directeur Hamed Shahbazi a reçu une attribution de 20 000 options d’achat d’actions non qualifiées au prix d’exercice de 14,13 $ par action. L’attribution vest à 100 % le 24/06/2026 et expire le 23/06/2035. Après la transaction, Shahbazi détient bénéficiairement 20 000 titres dérivés ; aucun changement dans la détention d’actions ordinaires n’a été signalé. La transaction a été déposée individuellement et rapportée comme une nouvelle attribution (code transaction « A »). Ce dépôt reflète la rémunération standard des administrateurs et introduit une dilution potentielle limitée (≈0,0 % des actions en circulation, en supposant une base typique de small cap) une fois exercée.

Niagen Bioscience, Inc. (NAGE) — Insider-Meldung Form 4: Am 24.06.2025 erhielt der Direktor Hamed Shahbazi eine Zuteilung von 20.000 nicht qualifizierten Aktienoptionen mit einem Ausübungspreis von 14,13 $ pro Aktie. Die Zuteilung wird zu 100 % am 24.06.2026 fällig und läuft am 23.06.2035 ab. Nach der Transaktion hält Shahbazi wirtschaftlich 20.000 derivative Wertpapiere; keine Änderung bei den Stammaktien wurde gemeldet. Die Transaktion wurde einzeln gemeldet und als neue Zuteilung (Transaktionscode „A“) ausgewiesen. Diese Meldung spiegelt die übliche Vergütung von Direktoren wider und führt nach Ausübung zu einer begrenzten potenziellen Verwässerung (≈0,0 % der ausstehenden Aktien, basierend auf einer typischen Small-Cap-Basis).

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Shahbazi Hamed

(Last) (First) (Middle)
10900 WILSHIRE BLVD. SUITE 600

(Street)
LOS ANGELES CA 90024

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Niagen Bioscience, Inc. [ NAGE ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/24/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) $14.13 06/24/2025 A 20,000 06/24/2026(1) 06/23/2035 Common Stock 20,000 $0 20,000 D
Explanation of Responses:
1. Option vests 100% on June 24, 2026.
Remarks:
/s/ Jeong James Lee, Attorney-in-Fact 07/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Niagen Bioscience (NAGE) report?

20,000 stock options were granted to director Hamed Shahbazi on 06/24/2025.

What is the exercise price of the NAGE options?

The options are exercisable at $14.13 per share.

When do the options granted to Hamed Shahbazi vest?

They vest 100 % on 06/24/2026.

When do the options expire?

The expiration date is 06/23/2035.

Did the filing report any common-stock purchases or sales?

No, only a new option grant; no common-stock transactions were disclosed.
Niagen Bioscience, Inc

NASDAQ:NAGE

NAGE Rankings

NAGE Latest News

NAGE Latest SEC Filings

NAGE Stock Data

1.00B
51.64M
34.79%
30%
2.72%
Biotechnology
Medicinal Chemicals & Botanical Products
Link
United States
LOS ANGELES